Hexanoic acid derivatives designed to inhibit prolyl hydroxylase domain containing protein 2 (PHD2)

Overview

This research focuses on the design and development of novel hexanoic acid derivatives that inhibit prolyl hydroxylase domain containing protein 2 (PHD2), a key oxygen-sensing enzyme. PHD2 regulates hypoxia-inducible factors (HIF) and is a validated target in conditions such as anemia, ischemic disease, and metabolic disorders. The proposed compounds are designed based on structural similarity to 2-oxoglutarate, the natural co-substrate of PHD2, and related compounds have demonstrated favorable coordination properties with ferrous iron, suggesting strong binding potential at the enzyme's active site.

Technical specifications

• Target enzyme: Prolyl hydroxylase domain containing protein 2 (PHD2), an iron- and 2-oxoglutarate-dependent dioxygenase
• Compound class: Hexanoic acid derivatives mimicking the natural co-substrate 2-oxoglutarate
• Mechanism of action: Competitive inhibition through structural mimicry of 2-oxoglutarate, with coordination to the catalytically active ferrous iron center
• Design rationale: Based on observed coordination properties of related compounds with ferrous iron
• Potential applications: Therapeutic intervention in HIF-regulated pathways, including anemia of chronic disease, ischemic conditions, and other hypoxia-related disorders

Technology readiness level

This research is at an early discovery stage. The hypothesis is supported by structural similarity to known PHD2 substrates and prior observations of related compounds' coordination behavior with ferrous iron. Further validation steps would include synthesis of the designed derivatives, biochemical assays to confirm PHD2 inhibition, and characterization of binding affinity and selectivity.